A primer on the management of antiviral resistance in chronic hepatitis B;Prévention et prise en charge de la résistance antivirale dans l'hépatite B chronique

Revue Medicale Suisse

Volumn 5, Issue 187, 2009, Pages 203-208

  Doerig, Christopher ^a   Sahli, Roland ^a   Telenti, Amalio ^a   Moradpour, Darius ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALPHA INTERFERON; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS PROTEIN;

ANTIVIRAL RESISTANCE; CLINICAL TRIAL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; REVIEW; TREATMENT FAILURE; VIRUS DETECTION; VIRUS DIAGNOSIS; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; HEPATITIS B, CHRONIC; HUMANS;

EID: 59649091505     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Negro F, Hadengue A. Le point sur le traitement antiviral de l'hépatite B chronique. Rev Med Suisse 2006; 2:1981-5.
2. * Dienstag JL. Hepatitis B virus infection. N Engl J Med 2008;359:1486-500.
3. * NIH Consensus development conference statement : Management of hepatitis B. http://consensus.nih. gov/2008/2008HepatitisBCDC120main.htm, 2008.
4. * EASL Clinical practice guideline : Management of chronic hepatitis B. J Hepatol 2009;50: in press (www. easl.ch/easl-cpg.asp).
5. * Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance : Mechanisms, detection and interpretation. J Hepatol 2006;44:593-606.
6. Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology 2006;43:1385-91.
7. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Addingon versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007;45:307-13.
8. * Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV : Standardization of nomenclature and assays and recommendations for management Hepatology 2007;46:254-65.
9. Villet S, Pichoud C, Villeneuve JP, et al. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient. Gastroenterology 2006;131: 1253-61.
10. Yim HJ, Hussain M, Liu Y, et al. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006;44:703-12.
11. * Keeffe EB, Zeuzem S, Koff RS, et al. Report of an international workshop : Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin Gastroenterol Hepatol 2007;5:890-7.
12. Pawlotsky JM, Dusheiko G, Hatzakis A, et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice : Recommendations for a standardized approach. Gastroenterology 2008;134:405-15.
13. Durantel D, Carrouee-Durantel S, Werle-Lapostolle B, et al. A new strategy for studying in vitro the drug susceptibility of clinical isolates of human hepatitis B virus. Hepatology 2004;40:855-64.
14. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001;33:751-7.
15. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008;48:88-98.